Trial Profile

A clinical trial of BIO 300 to mitigate erectile dysfunction in men undergoing radiation treatment for prostate cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Genistein (Primary)
Indications Erectile dysfunction
Focus Therapeutic Use
Sponsors Humanetics Corporation

Most Recent Events

10 Oct 2022 New trial record
05 Oct 2022 According to a Humanetics Corporation media release, the company has received FDA clearance of Investigational New Drug (IND) application for BIO 300 to mitigate erectile dysfunction in men undergoing radiation treatment for prostate cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com